Eli Lilly to buy psychedelics maker AtaiBeckley for $2.8 billion as experimental treatments gain traction

The deal for AtaiBeckley gives Lilly access to experimental drugs based on DMT and MDMA.

By CNBC · CNBC

The deal for AtaiBeckley gives Lilly access to experimental drugs based on DMT and MDMA.